Despite the competitive threat posed by Eli Lilly’s acquisition of Scorpion Therapeutics’ STX-478, which has shown promising efficacy in several cancer types, Relay Therapeutics’ RLY-2608 ...

NJ Advance Media will have you covered with all the action, but for now, head down below to find our previews highlighting our predictions and teams to watch for all 12 relay championship meets.

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. A deal is likely to be reached in the coming days ahead of the ...